INR Target for Mechanical Mitral Valve Replacement
For patients with a mechanical mitral valve prosthesis, maintain an INR goal of 3.0 (range 2.5-3.5). This target balances the higher thromboembolism risk associated with mitral position valves against bleeding complications 1, 2.
Key Differences by Valve Type and Position
Mechanical Mitral Valve
- Target INR: 3.0 (range 2.5-3.5) 1, 2
- The mitral position carries inherently higher thromboembolism risk compared to aortic position
- The GELIA study demonstrated that lower INR ranges (2.0-3.5) were associated with worse survival compared to higher target ranges (2.5-4.5) in mechanical mitral prostheses 1
- A recent 2023 randomized trial (PROACT Mitral) attempted to establish noninferiority of low-dose warfarin (INR 2.0-2.5) versus standard-dose (INR 2.5-3.5) but failed to demonstrate noninferiority, reinforcing the need for standard-intensity anticoagulation 3
Mechanical Aortic Valve (for comparison)
- Target INR: 2.5 (range 2.0-3.0) if no additional risk factors 1, 2
- Target INR: 3.0 (range 2.5-3.5) if additional risk factors present (atrial fibrillation, prior thromboembolism, LV dysfunction, hypercoagulable state, older-generation prosthesis) 1, 2
Bioprosthetic (Tissue) Valves
- No long-term anticoagulation required for patients in sinus rhythm 1, 2
- Aspirin 75-100 mg daily is reasonable in the absence of other indications for anticoagulation 2
- For the first 3-6 months post-operatively, warfarin with INR goal 2.5 (range 2.0-3.0) is reasonable if bleeding risk is low 2
- After the initial 3-6 month period, aspirin alone suffices unless other indications exist (e.g., atrial fibrillation)
Additional Antiplatelet Therapy
Consider adding aspirin 75-100 mg daily to warfarin in mechanical valve patients when there is a separate indication for antiplatelet therapy and bleeding risk is low 1, 2. However, recognize that this increases bleeding risk, particularly if INR exceeds 3.0-4.5 4.
Critical Pitfalls to Avoid
- Do not use lower INR targets for mechanical mitral valves: The 2023 PROACT trial definitively showed that INR 2.0-2.5 is inadequate 3
- Patient compliance challenges: Studies show patients achieve target INR 2.0-3.5 about 75% of the time, but only 44.5% of the time for target INR 3.0-4.5 1. This reality supports the 2.5-3.5 range as optimal
- Never use direct oral anticoagulants (DOACs): Dabigatran is contraindicated in mechanical valve patients 2
- Bleeding risk increases substantially above INR 3.5-4.0, even in patients with mitral prostheses 4, 5
Bridging Considerations
For mechanical mitral valves, bridging anticoagulation is recommended during periods when INR is subtherapeutic 1, unlike mechanical aortic valves without risk factors where bridging is not needed.